 Asian Scientist Magazine | Takeda's Orteronel (TAK-700) Enters Phase III Clinical Trials For Prostate Cancer Asian Scientist Magazine The first (C21004) is a randomized, double-blind and multi-center trial of prednisolone plus orteronel or placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. The primary endpoints are Overall Survival and ... |
